drugset / Trial / NCT02204085
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2
Completed
33 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.
Timeline
- Start
- 2014-09
- Primary completion
- 2025-09
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | — |
| Subject | GO-203-2C | Protein / enzyme biologic | — | — |